Free Trial

Immunome (IMNM) FDA Events

Immunome logo
$8.93 +0.04 (+0.42%)
As of 03:58 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.
FDA Events for Immunome (IMNM)

This section highlights FDA-related milestones and regulatory updates for drugs developed by Immunome (IMNM). Over the past two years, Immunome has reported clinical trial outcomes, regulatory submissions, approvals, and other FDA events for drugs and therapies such as IM-1021. For definitions of regulatory abbreviations such as NDA, BLA, or PDUFA, see the event status legend.

IM-1021 - FDA Regulatory Timeline and Events

IM-1021 is a drug developed by Immunome for the following indication: In Cancer therapies. This drug is under review by the U.S. Food and Drug Administration (FDA). Below is a timeline of key regulatory milestones for this therapy.

Immunome FDA Events - Frequently Asked Questions

As of now, Immunome (IMNM) has not received any FDA approvals for its therapy in the last two years.

In the past two years, Immunome (IMNM) has reported FDA regulatory activity for IM-1021.

The most recent FDA-related event for Immunome occurred on March 10, 2025, involving IM-1021. The update was categorized as "Dosing Update," with the company reporting: "Immunome, Inc. announced that the first patient has been dosed in the Phase 1, first-in-human trial of IM-1021, a ROR1-targeted ADC."

Currently, Immunome has one therapy (IM-1021) targeting the following condition: In Cancer therapies.

More FDA Event Resources from MarketBeat

  • NDA: New Drug Application
  • ANDA: Abbreviated New Drug Application
  • sNDA: Supplemental New Drug Application
  • BLA: Biologics License Application
  • sBLA: Supplemental Biologics License Application
  • FDA Approved: Approved by the FDA
  • EMA: European Medicines Agency
  • CE Mark: European Union Certification
  • NMPA: China National Medical Products Administration
  • MHLW: Japanese Ministry of Health
  • FDA Meeting: Consultation with FDA
  • Pre-IND: Pre-Investigational New Drug Meeting
  • Breakthrough Therapy: Special FDA designation for promising therapies
  • Fast Track: Accelerated FDA approval pathway
  • Orphan Drug: Designation for rare disease treatments
  • RPD: Rare Pediatric Disease Designation
  • RMAT: Regenerative Medicine Advanced Therapy
  • DSMB Review: Data Safety Monitoring Board Review
  • IDMC Review: Independent Data Monitoring Committee
  • MAA: MHRA Marketing Authorization Application
  • RTF: Refusal to File (Rejected Application)
  • 510(k): FDA Clearance for Medical Devices
  • Rolling Submission: Staggered regulatory review process

This page (NASDAQ:IMNM) was last updated on 7/10/2025 by MarketBeat.com Staff
From Our Partners